
JNJ-42226314 is a competitive, highly селективный and reversible non-covalent monoacylglycerol lipase (MAGL) ингибитор. JNJ-42226314 demonstrates dose-dependent enhancement of the major endocannabinoid 2-arachidonoylglycerol (2-AG) as well as efficacy in models of neuropathic and inflammatory pain.
JNJ-42226314 is a competitive, highly selective and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor. JNJ-42226314 demonstrates dose-dependent enhancement of the major endocannabinoid 2-arachidonoylglycerol (2-AG) as well as efficacy in models of neuropathic and inflammatory pain.
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.